Literature DB >> 20189258

Carbon ion radiation therapy for high-risk meningiomas.

Stephanie E Combs1, Christian Hartmann, Anna Nikoghosyan, Oliver Jäkel, Christian P Karger, Thomas Haberer, Andreas von Deimling, Marc W Münter, Peter E Huber, Jürgen Debus, Daniela Schulz-Ertner.   

Abstract

BACKGROUND: We analyzed outcome after a carbon ion boost in combination with precision photon radiation therapy in patients with meningiomas. PATIENTS AND METHODS: Ten patients with meningiomas were treated with carbon ion RT as part of a Phase I/II trial. Carbon ion RT was conducted in conjunction with fractionated stereotactic RT (FSRT) or intensity-modulated RT (IMRT). Eight patients were treated as primary RT, in 2 patients carbon ion RT was performed as re-irradiation. Carbon ion RT was applied with a median dose of 18 GyE, and photon RT was applied with a median dose of 50.4 Gy. Two patients with a history of former irradiation received 18GyE of carbon ion RT and a reduced dose of photon treatment.
RESULTS: The median follow-up time was 77 months. Five patients died during follow-up, of which four died of tumor progression. In the group treated in the primary situation, actuarial survival rates after RT were 75% and 63% at 5 and 7 years. After re-irradiation, both patients died at 10 and 67 months, respectively. Actuarial local control rates after primary RT were 86% and 72% at 5 and 7 years. Two patients developed tumor recurrence after re-irradiation, 6 and 67 months after treatment.
CONCLUSION: In conclusion, carbon ion radiation shows promising results in patients with atypical or anaplastic meningiomas. Further evaluation in a larger, prospective study in comparison to proton RT or modern photon RT is needed to corroborate these results. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189258     DOI: 10.1016/j.radonc.2009.12.029

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  18 in total

Review 1.  The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature.

Authors:  M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari
Journal:  J Neurooncol       Date:  2011-07-31       Impact factor: 4.130

Review 2.  Particle therapy in the future of precision therapy.

Authors:  Lukas Schaub; Semi Ben Harrabi; Juergen Debus
Journal:  Br J Radiol       Date:  2020-08-14       Impact factor: 3.629

3.  Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.

Authors:  Stephanie E Combs; Meinhard Kieser; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Anna Nikoghosyan; Renate Haselmann; Andreas Unterberg; Wolfgang Wick; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-09-06       Impact factor: 4.430

4.  Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.

Authors:  Stephanie E Combs; Lutz Edler; Iris Burkholder; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Andreas Unterberg; Wolfgang Wick; Jürgen Debus; Renate Haselmann
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

Review 5.  Current experimental therapies for atypical and malignant meningiomas.

Authors:  Andres M Corona; Long Di; Ashish H Shah; Raphael Crespo; Daniel G Eichberg; Victor M Lu; Evan M Luther; Ricardo J Komotar; Michael E Ivan
Journal:  J Neurooncol       Date:  2021-05-05       Impact factor: 4.130

6.  Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.

Authors:  Stefan Rieken; Daniel Habermehl; Thomas Haberer; Oliver Jaekel; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2012-03-21       Impact factor: 3.481

7.  Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas.

Authors:  Katsura Kosaki; Swantje Ecker; Daniel Habermehl; Stefan Rieken; Oliver Jäkel; Klaus Herfarth; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2012-03-22       Impact factor: 3.481

8.  Postoperative radiotherapy for meningiomas - a decision-making analysis.

Authors:  Thomas Hundsberger; Paul Martin Putora; Galina Farina Fischer; Detlef Brügge; Nicolaus Andratschke; Brigitta Gertrud Baumert; Davide Giovanni Bosetti; Francesca Caparrotti; Evelyn Herrmann; Alexandros Papachristofilou; Susanne Rogers; Lucia Schwyzer; Daniel Rudolf Zwahlen
Journal:  BMC Cancer       Date:  2022-05-04       Impact factor: 4.638

9.  The Efficacy and Safety of Carbon Ion Radiotherapy for Meningiomas: A Systematic Review and Meta-Analysis.

Authors:  Jie-Yun Li; Jing-Wen Li; Yuan-Chang Jin; Mei-Xuan Li; Li-Ping Guo; Zhi-Tong Bing; Qiu-Ning Zhang; Fei Bai; Xiao-Hu Wang; Xiu-Xia Li; Ke-Hu Yang
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

10.  Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Tomo Miyata; Taichiro Toho; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  Radiat Oncol       Date:  2015-07-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.